Spyre Therapeutics Statistics
Total Valuation
SYRE has a market cap or net worth of $1.40 billion. The enterprise value is $1.16 billion.
Important Dates
The last earnings date was Thursday, November 7, 2024, after market close.
| Earnings Date | Nov 7, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
SYRE has 51.43 million shares outstanding. The number of shares has increased by 845.79% in one year.
| Current Share Class | 51.43M |
| Shares Outstanding | 51.43M |
| Shares Change (YoY) | +845.79% |
| Shares Change (QoQ) | +12.30% |
| Owned by Insiders (%) | 10.03% |
| Owned by Institutions (%) | 75.51% |
| Float | 32.94M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 8.24 |
| P/TBV Ratio | 8.24 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 7.32
| Current Ratio | 7.32 |
| Quick Ratio | 7.23 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -91.62% and return on invested capital (ROIC) is -51.98%.
| Return on Equity (ROE) | -91.62% |
| Return on Assets (ROA) | -38.81% |
| Return on Capital (ROIC) | -51.98% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$7.16M |
| Employee Count | 30 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, SYRE has paid $50,000 in taxes.
| Income Tax | 50,000 |
| Effective Tax Rate | n/a |
Dividends & Yields
SYRE does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -845.79% |
| Shareholder Yield | -845.79% |
| Earnings Yield | -15.19% |
| FCF Yield | -10.69% |
Analyst Forecast
The average price target for SYRE is $48.57, which is 78.96% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $48.57 |
| Price Target Difference | 78.96% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 9 |
| Revenue Growth Forecast (5Y) | -17.43% |
| EPS Growth Forecast (5Y) | -39.43% |
Stock ForecastsStock Splits
The last stock split was on September 8, 2023. It was a reverse split with a ratio of 0.04:1.
| Last Split Date | Sep 8, 2023 |
| Split Type | Reverse |
| Split Ratio | 0.04:1 |
Scores
SYRE has an Altman Z-Score of 3.09 and a Piotroski F-Score of 2.
| Altman Z-Score | 3.09 |
| Piotroski F-Score | 2 |